ERAS Stock Analysis: Erasca | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 4.914m USD | 12M Return: 543.3% | US29479A1088 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 65.8M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 5.2 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Erasca, Inc. is a clinical-stage precision oncology company focused on discovering, developing, and commercializing therapies for patients with cancers driven by the RAS/MAPK pathway, a signaling cascade frequently implicated in tumor growth. The companys pipeline includes ERAS-0015, a pan-RAS molecular glue; ERAS-4001, a pan-KRAS inhibitor; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody.
To support its pipeline, Erasca maintains a network of license and collaboration agreements with multiple partners, including Guangzhou Joyo Pharmatech (pan-RAS inhibitors), Medshine Discovery (pan-KRAS inhibitors), Novartis Pharma AG (naporafenib), NiKang Therapeutics (ERAS-601), Asana BioSciences (ERAS-007), and Tango Therapeutics (a clinical trial collaboration for ERAS-0015).
Erasca was incorporated in 2018 and is headquartered in San Diego, California, and is listed on the NASDAQ under the ticker ERAS. As a clinical-stage biotechnology company, it has not yet commercialized any products, and its value is primarily derived from the development potential of its drug candidates rather than current revenue.
- ERAS-0015 pan-RAS molecular glue Phase 1 data readout
- Naporafenib combination efficacy data from Novartis-partnered trial
- Cash runway extension through pipeline prioritization and cost reduction
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.23 > 0.02 and ΔFCF/TA -0.27 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.23 > 3% & CFO -98.0m > Net Income -287.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 8.29 > 1.5 & < 3 |
| Outstanding Shares: last quarter (311.3m) vs 12m ago 9.87% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.94%; Δ -0.94% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.56 (Total Current Assets 278.4m - Total Current Liabilities 33.6m) / Total Assets 435.1m |
| B: -2.57 (Retained Earnings -1.12b / Total Assets 435.1m) |
| C: -0.65 (EBIT TTM -287.2m / Avg Total Assets 440.2m) |
| D: 4.94 (Book Value of Equity 361.9m / Total Liabilities 73.2m) |
| Altman-Z'' = -3.89 = D |
As of November 07, 2026, the stock is trading at USD 14.41 with a total of 4,030,116 shares traded. Over the past week, the price has changed by +0.42%, over one month by +0.77%, over three months by -21.13% and over the past year by +543.30%.
Current recommended Stop Loss: 12.70 (which is 11.9% or 1.6 ATR below the current price).
Erasca has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy ERAS.
- StrongBuy: 5
- Buy: 2
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 24.1 | 67.3% |
P/B = 13.8506
Revenue TTM = 0.0 USD
EBIT TTM = -287.2m USD
EBITDA TTM = -284.3m USD
Long Term Debt = 39.3m USD (estimated: total debt 44.7m - short term 5.44m)
Short Term Debt = 5.44m USD (from shortTermDebt, last quarter)
Debt = 44.7m USD (from shortLongTermDebtTotal, last quarter) (leases 44.7m already included)
Net Debt = -224.0m USD (calculated: Debt 44.7m - CCE 268.7m)
Enterprise Value = 4.69b USD (4.91b + Debt 44.7m - CCE 268.7m)
Interest Coverage Ratio = unknown (Ebit TTM -287.2m / Interest Expense TTM 0.0)
EV/FCF = -47.82x (Enterprise Value 4.69b / FCF TTM -98.1m)
FCF Yield = -2.09% (FCF TTM -98.1m / Enterprise Value 4.69b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 3.11m) / Revenue TTM)
Tobins Q-Ratio = 10.78 (Enterprise Value 4.69b / Total Assets 435.1m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 44.7m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -226.9m (EBIT -287.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.29 (Total Current Assets 278.4m / Total Current Liabilities 33.6m)
Debt / Equity = 0.12 (Debt 44.7m / totalStockholderEquity, last quarter 361.9m)
Debt / EBITDA = 0.79 (negative EBITDA) (Net Debt -224.0m / EBITDA -284.3m)
Debt / FCF = 2.28 (negative FCF - burning cash) (Net Debt -224.0m / FCF TTM -98.1m)
Total Stockholder Equity = 357.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -65.25% (Net Income -287.2m / Total Assets 435.1m)
RoE = -80.43% (Net Income TTM -287.2m / Total Stockholder Equity 357.1m)
RoCE = -72.46% (EBIT -287.2m / Capital Employed (Equity 357.1m + L.T.Debt 39.3m))
RoIC = -55.76% (negative operating profit) (NOPAT -226.9m / Invested Capital 406.9m)
WACC = 10.56% (E(4.91b)/V(4.96b) * Re(10.66%) + D(44.7m)/V(4.96b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 10.66% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 90.84 | Cagr: 52.24%
[DCF] Fair Price = unknown (Cash Flow -98.1m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.14 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.13 | Chg30d=-7.60% | Revisions=-30% | Analysts=8
EPS current Year (2026-12-31): EPS=-0.98 | Chg30d=-2.22% | Revisions=-25% | GrowthEPS=-121.9% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-0.62 | Chg30d=-11.80% | Revisions=-42% | GrowthEPS=+36.2% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -39% (up=7, down=18)